Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928198 | 0.87 | PARP1 (0.37) | CYP1A2PARP1MTNR1AMTNR1BPDK2 | |
| SCHEMBL9928149 | 0.86 | PARP1 (0.33) | CYP1A2PARP1MTNR1AMTNR1BPDK2 | |
| SCHEMBL9928202 | 0.85 | PARP1 (0.33) | CYP1A2PARP1MTNR1AMTNR1BPDK2 | |
| SCHEMBL9928196 | 0.83 | PARP1 (0.32) | PARP1MTNR1AMTNR1B | |
| SCHEMBL9928197 | 0.83 | PARP1 (0.32) | PARP1MTNR1AMTNR1B | |
| SCHEMBL9928193 | 0.83 | PARP1 (0.32) | PARP1MTNR1AMTNR1B | |
| SCHEMBL9928194 | 0.83 | PARP1 (0.32) | PARP1MTNR1AMTNR1B | |
| SCHEMBL9928195 | 0.83 | PARP1 (0.32) | PARP1MTNR1AMTNR1B | |
| SCHEMBL9928153 | 0.82 | MTNR1A (0.32) | PARP1MTNR1AMTNR1B | |
| SCHEMBL9928199 | 0.81 | ALOX5AP (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120145974-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | CRY2, CYP2J2, NR0B2 | CYP1A2 22/4885CYP2C19 122/4885KMT2A 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.